Metabolon Closes Additional Financing
News Oct 27, 2009
Metabolon, Inc., a company involved in metabolomics-driven biomarker discovery and analysis, announced today that it has closed an additional $6 million in its Series C funding round. This brings the total funding raised in the company’s series C round to $12.3 million.
Syngenta Ventures, the corporate venture capital subsidiary of Syngenta, and Fletcher Spaght Ventures invested as new investors joining Sevin Rosen Funds, Aurora Funds, Harris and Harris Group, Fulcrum Financial Partners and Alexandria Equities as Series C investors.
As a part of the financing, Carol Marino, Ph.D., Vice President of Syngenta Ventures and Guy Fish, MD, Vice President of Fletcher Spaght will join Metabolon’s Board of Directors. Syngenta, a leading global agribusiness company, also expanded a previously announced research collaboration with Metabolon.
Metabolon offers global biochemical profiling (metabolomic) services to researchers working in drug safety and toxicology, bioprocess optimization, consumer products and other areas which benefit from insight into complex biochemical processes and how they change in response to experimental variables.
The company’s technology has been used to identify biochemical biomarkers useful for the development of a wide range of diagnostics. These markers are being applied to the development of its own proprietary diagnostic tools for prostate cancer and insulin resistance.
'Body-on-a-Chip' Could Advance Drug EvaluationNews
MIT engineers have developed new technology that could be used to evaluate new drugs and detect possible side effects before the drugs are tested in humans. Using a microfluidic platform that connects engineered tissues from up to 10 organs, the researchers can accurately replicate human organ interactions for weeks at a time.READ MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.
Study Debunks Fears of Increased Teen Suicide Risk From TamifluNews
Researchers from the University of Illinois at Chicago suggests that the drug oseltamivir - commonly known as Tamiflu - does not cause an increased risk of suicide in pediatric patients.READ MORE